Metabolic Brain Disease

, Volume 11, Issue 1, pp 89–94

Thiamine therapy in Alzheimer's disease

  • Yasuyo Mimori
  • Hiroyuki Katsuoka
  • Shigenobu Nakamura
Article

DOI: 10.1007/BF02080934

Cite this article as:
Mimori, Y., Katsuoka, H. & Nakamura, S. Metab Brain Dis (1996) 11: 89. doi:10.1007/BF02080934

Abstract

Fursultiamine (TTFD), a derivative of thiamine, at an oral dose of 100 mg/day had a mild beneficial effect in patients with Alzheimer's disease in a 12-week open trial. The improvement could be observed not only in their emotional or other mental symptoms but also in intellectual function. Only mildly impaired subjects showed cognitive improvement. Alzheimer patients' blood levels of thiamine before the trial were within the normal range. No adverse reactions were observed and all patients tolerated the trial well. TTFD could afford an alternate treatment to large doses of thiamine hydrochloride in Alzheimer patients. However, further investigations of the therapeutic implications of thiamine and its possible etiologic clues to Alzheimer's disease are necessary.

Keywords

thiamine fursultiamine Alzheimer's disease cognitive function 

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Yasuyo Mimori
    • 1
  • Hiroyuki Katsuoka
    • 1
  • Shigenobu Nakamura
    • 1
  1. 1.The Third Department of Internal MedicineHiroshima University School of MedicineMinamiku, HiroshimaJapan

Personalised recommendations